31
Participants
Start Date
March 12, 2021
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2027
Romosozumab Prefilled Syringe [Evenity]
2 syringes of 105 MG/1.17 mL subcutaneous solution injected one after the other, once a month from study baseline through 11 month visit
Denosumab 60 MG/ML Prefilled Syringe [Prolia]
1 subcutaneous injection of 60 mg/mL every six months from study 12 month visit through the 24 month visit. Injections occur at the 12 and 18 month visits.
Columbia University Irving Medical Center, New York
Collaborators (1)
Amgen
INDUSTRY
Columbia University
OTHER